Respiratory Syncytial Virus Related Readmission in Preterm Infants Less than 34 weeks' Gestation Following Discharge from a Neonatal Intensive Care Unit in Korea

被引:9
作者
Lee, Jang Hoon [1 ]
Kim, Chun Soo [2 ]
Chang, Yun Sil [3 ]
Choi, Jung-Hwan [4 ]
机构
[1] Ajou Univ, Sch Med, Dept Pediat, Suwon 441749, South Korea
[2] Keimyung Univ, Sch Med, Dept Pediat, Daegu, South Korea
[3] Sungkyunkwan Univ, Samsung Med Ctr, Dept Pediat, Seoul, South Korea
[4] Seoul Natl Univ, Coll Med, Dept Pediat, Seoul 03080, South Korea
关键词
Infants; Premature; Patient Readmission; Respiratory Syncytial Virus; Bronchopulmonary Dysplasia; Palivizumab; PALIVIZUMAB PROPHYLAXIS; PREMATURE-INFANTS; INFECTION; CHILDREN; REHOSPITALIZATION; HOSPITALIZATIONS; EPIDEMIOLOGY; DISEASE; BRONCHIOLITIS; OUTCOMES;
D O I
10.3346/jkms.2015.30.S1.S104
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This study was done to evaluate respiratory syncytial virus (RSV) related readmission (RRR) and risk factors of RRR in preterm infants < 34 weeks gestational age (GA) within 1 yr following discharge from the neonatal intensive care unit (NICU). Infants (n = 1,140) who were born and admitted to the NICUs of 46 hospitals in Korea from April to September 2012, and followed up for > 1 yr after discharge from the NICU, were enrolled. The average GA and birth weight of the infants was 30(+5) +/- 2(+5) weeks and 1,502 +/- 474 g, respectively. The RRR rate of enrolled infants was 8.4% (96/1,140), and RSV accounted for 58.2% of respiratory readmissions of infants who had laboratory tests confirming etiological viruses. Living with elder siblings (odd ratio [OR], 2.68; 95% confidence interval [CI], 1.68-4.28; P < 0.001), and bronchopulmonary dysplasia (BPD) (OR, 2.95; 95% CI, 1.44-6.04; P = 0.003, BPD vs. none) increased the risk of RRR. Palivizumab prophylaxis (OR, 0.06; 95% CI, 0.03-0.13; P < 0.001) decreased the risk of RRR. The risk of RRR of infants of 32-33 weeks' gestation was lower than that of infants < 26 weeks' gestation (OR, 0.11; 95% CI, 0.02-0.53; P = 0.006). This was a nationwide study that evaluated the rate and associated risk factors of RRR in Korean preterm infants. Preterm infants with BPD or living with siblings should be supervised, and administration of palivizumab to prevent RRR should be considered.
引用
收藏
页码:S104 / S110
页数:7
相关论文
共 30 条
[1]   DEVELOPMENT OF THE IMMUNE-SYSTEM IN VERY-LOW-BIRTH-WEIGHT (LESS THAN 1500 G) PREMATURE-INFANTS - CONCENTRATIONS OF PLASMA IMMUNOGLOBULINS AND PATTERNS OF INFECTIONS [J].
BALLOW, M ;
CATES, KL ;
ROWE, JC ;
GOETZ, C ;
DESBONNET, C .
PEDIATRIC RESEARCH, 1986, 20 (09) :899-904
[2]  
Brady MT, 2014, PEDIATRICS, V134, pE620, DOI [10.1542/peds.2014-1666, 10.1542/peds.2014-1665]
[3]   Rehospitalization because of respiratory syncytial virus infection in premature infants younger than 33 weeks of gestation:: a prospective study [J].
Carbonell-Estrany, X ;
Quero, J ;
Bustos, G ;
Cotero, A ;
Doménech, E ;
Figueras-Aloy, J ;
Fraga, JM ;
García, LG ;
García-Alix, A ;
Del Río, MG ;
Krauel, X ;
Sastre, JBL ;
Narbona, E ;
Roqués, V ;
Hernández, SS ;
Zapatero, M .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2000, 19 (07) :592-597
[4]   Outcomes of Palivizumab Prophylaxis for Respiratory Syncytial Virus Infection in Preterm Children with Bronchopulmonary Dysplasia at a Single Hospital in Korea from 2005 to 2009 [J].
Chang, Seung Gu ;
Park, Moon Sung ;
Yu, Jae Eun .
JOURNAL OF KOREAN MEDICAL SCIENCE, 2010, 25 (02) :251-256
[5]  
Connor E, 1997, PEDIATRICS, V99, P93
[6]   The clinical and health economic burden of respiratory syncytial virus disease among children under 2 years of age in a defined geographical area [J].
Deshpande, SA ;
Northern, V .
ARCHIVES OF DISEASE IN CHILDHOOD, 2003, 88 (12) :1065-1069
[7]   Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease [J].
Feltes, TF ;
Cabalka, AK ;
Meissner, C ;
Piazza, FM ;
Carlin, DA ;
Top, FH ;
Connor, EM ;
Sondheimer, HM .
JOURNAL OF PEDIATRICS, 2003, 143 (04) :532-540
[8]   CDC DEFINITIONS FOR NOSOCOMIAL INFECTIONS, 1988 [J].
GARNER, JS ;
JARVIS, WR ;
EMORI, TG ;
HORAN, TC ;
HUGHES, JM .
AMERICAN JOURNAL OF INFECTION CONTROL, 1988, 16 (03) :128-140
[9]   Administration of the first dose of palivizumab immunoprophylaxis against respiratory syncytial virus in infants before hospital discharge: What is the evidence for its benefit? [J].
Geskey, JM ;
Ceneviva, GD ;
Brummel, GL ;
Graff, GR ;
Javier, MC .
CLINICAL THERAPEUTICS, 2004, 26 (12) :2130-2137
[10]  
Jobe Alan H., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1723